...
首页> 外文期刊>Clinical therapeutics >Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study.
【24h】

Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study.

机译:磺胺甲恶唑在低海拔和急性暴露于高海拔地区的男性中国志愿者与长期居住在高海拔地区的受试者之间的药代动力学比较:一项开放性,对照,前瞻性研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. OBJECTIVE: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (approximately 400 m [approximately 1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (approximately 3780 m [approximately 12,400 ft]); and a separate group of volunteers who had been living at high altitude (approximately 3780 m) for >or=1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N(4)-acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. RESULTS: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19-24 years]; weight, 64.2 [5.9] kg [range, 56.0-75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0-180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19-24 years]; weight, 62.4 [8.2] kg [range, 50.0-75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0-182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group (P < 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t((1/2)), 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT(0-48)), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (k(e)), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours(-1); AUC(0-48), 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) micro/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t((1/2)) was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- (P < 0.05) and chronic-exposure (P < 0.001) groups, respectively, than in the low-altitude group. AUC(0-48) was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P < 0.05). CONCLUSION: This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of approximatel
机译:背景:磺胺甲恶唑是一种抗菌磺酰胺,主要与甲氧苄氨嘧啶联用,用于治疗多种细菌感染。尽管已被用作预防与高海拔相关的呼吸道感染的方法,但关于磺胺甲恶唑在高海拔地区(尤其是中国人)中的药代动力学特性的信息很少。目的:本研究旨在探讨磺胺甲恶唑在急性和慢性高海拔暴露后对健康中国人的药代动力学。方法:在健康的中国男性志愿者中进行了一项开放标签,对照,前瞻性研究。分为三组的志愿者口服给予1200 mg的磺胺甲恶唑:低海拔地区(大约400 m [大约1300 ft])的志愿者;这些相同的志愿者在暴露于高海拔(约3780 m [约12400 ft])后16小时(急性)后;以及另外一组在高海拔(约3780 m)或超过1年(长期)生活的志愿者。低海拔组和急性暴露组的相隔了1周的冲洗期。在给药药物(基线)之前和0.25、0.5、0.75、1、1.5、2、3、4、6、8、12、24、36和48小时时,从留置的静脉导管中采集血液样本到肝素化管中研究药物给药后。通过HPLC测定全血,血浆和血浆水中的磺胺甲基异恶唑及其血浆中的代谢产物N(4)-乙酰基磺胺甲基恶唑。使用血液化学测试,连续12导联心电图和血压监测确定耐受性。结果:共有23名健康的中国男性志愿者在低海拔地区生活(种族,均为汉族;平均[SD]年龄为20.4 [1.1]年[范围,19-24岁];体重为64.2 [5.9] kg [范围] ,身高56.0-75.0公斤];身高172.1 [4.9]厘米[范围,163.0-180.0厘米])和21名健康的中国男性志愿者,生活在高海拔地区(种族,全汉族;平均[SD]年龄:21.2 [1.3]年龄[19-24岁]年;体重62.4 [8.2] kg [范围50.0-75.0 kg];身高171.4 [5.8] cm [范围162.0-182.0 cm])。每组20人完成了研究。暴露于高海拔后,血浆水中磺胺甲恶唑的浓度显着下降;因此,与低海拔组(65.7%;两者,P <0.001)相比,急性(80.4%)和慢性暴露(72.5%)组的蛋白质结合显着更高。在低海拔,急性和慢性暴露组中,磺胺甲基异恶唑与红细胞的结合分别为6.0%,6.9%和9.3%。慢性暴露组比低海拔组高55%(P <0.001)。给予次磺胺甲恶唑后,分别在低海拔,急性和慢性暴露组中记录以下值:平均值(SD)t((1/2)),9.30(1.11),10.37(0.88)和11.15(1.53)小时;平均停留时间(MRT(0-48)),12.06(0.94),13.15(0.67)和13.00(1.01)小时;消除速率常数(k(e)),0.076(0.010),0.067(0.006)和0.063(0.009)小时(-1); AUC(0-48),1202.5(238.3),1416.3(202.6)和1298.5(256.0)micro / mL / h;和清除率(CL),1.01(0.22),0.83(0.13)和0.92(0.22)L / kg / h。与低海拔组相比,急性和慢性暴露组的t((1/2))分别高11.5%和19.9%,而慢性暴露组的t((1/2))比急性组高7.5%。接触组。与低海拔组相比,急性(P <0.05)和慢性暴露(P <0.001)组的MRT分别高9.0%和7.8%。与低海拔组相比,急性暴露组的AUC(0-48)高17.8%,CL低17.8%(均P <0.05)。结论:本研究发现,这些健康的男性中国受试者在急性或慢性暴露于大约1升的海拔高度后,磺胺甲恶唑的分布发生了显着变化。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号